Home > Insider Trading > Filing (0001140361-10-021422)

Filing Details

Accession Number:: 0001140361-10-021422
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-05-14 13:00:00
Reporting Period:: 2010-05-13

Filing Date:: 2010-05-14
Accepted Time:: 2010-05-14 16:44:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380185	Fuad El-Hibri	2273 Research Blvd., Suite 400 Rockville MD 20850	Ceo And Chairman	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-05-13	27,000	$10.13	901,320	No	4	M	Direct
Common Stock	Disposition	2010-05-13	27,000	$17.04	874,320	No	4	S	Direct
Common Stock	Disposition	2010-05-13	25,000	$17.03	1,524,155	No	4	S	Indirect	By Biovac, L.L.C.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	S	Indirect	By Biovac, L.L.C.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2010-05-13	27,000	$0.00	27,000	$10.13

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2013-12-12	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,643,794	Indirect	By Intervac, L.L.C.
Common Stock	5,011	Indirect	By Karim El-Hibri Trust
Common Stock	5,011	Indirect	By Yusra El-Hibri Trust
Common Stock	5,011	Indirect	By Faiza El-Hibri Trust
Common Stock	2,965,043	Indirect	By BioPharm, L.L.C.

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. El-Hibri on March 9, 2010. Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan that vest in three equal annual installments beginning March 9, 2011.
The sales price for the transaction on May 13, 2010 is the weighted average sales price for the transactions. The prices range from $17.00 to $17.16. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Biovac, L.L.C. on March 9, 2010. Biovac, L.L.C. was the direct owner of the shares of Common Stock sold pursuant to the Rule 10b5-1 trading plan, and was or is the direct owner of the shares of Common Stock reported as beneficially owned immediately following each of the reported sales. Both before and after the reported sales, Mr. El-Hibri held individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
The sales price for the transaction on May 13, 2010 is the weighted average sales price for the transactions. The prices range from $17.00 to $17.16. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Mr. El-Hibri holds with his wife, as tenants by the entirety, an aggregate 41.1072% equity interest in Intervac, L.L.C. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Intervac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest therein in 2,731,079 shares.
These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 2,965,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,191,058 shares.
The option vested in three equal installments on December 12, 2007, December 12, 2008 and December 12, 2009.